Marshall Wace’s Precision BioSciences DTIL Stock Holding History

Marshall Wace’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-415,671	Closed	-$2.29M	–	3295
2026 Q1	$2.29M	Buy	415,671 +344,756	+486%	+$1.59M	﹤0.01%	1711
2025 Q4	$295K	Buy	+70,915	New	+$403K	﹤0.01%	2453
2024 Q4	–	Sell	-12,515	Closed	-$112K	–	2677
2024 Q3	$112K	Buy	+12,515	New	+$120K	﹤0.01%	2363
2023 Q4	–	Sell	-13,753	Closed	-$140K	–	2266
2023 Q3	$140K	Sell	13,753 -7,879	-36%	-$121K	﹤0.01%	2016
2023 Q2	$344K	Sell	21,632 -12,351	-36%	-$282K	﹤0.01%	2102
2023 Q1	$765K	Buy	33,983 +27	+0.1%	+$890	﹤0.01%	1930
2022 Q4	$1.21M	Sell	33,956 -45,452	-57%	-$1.8M	﹤0.01%	2002
2022 Q3	$3.1M	Sell	79,408 -3,289	-4%	-$156K	0.01%	1723
2022 Q2	$3.97M	Buy	+82,697	New	+$4.85M	0.01%	1521
2021 Q4	–	Sell	-6,004	Closed	-$2.08M	–	3943
2021 Q3	$2.08M	Buy	+6,004	New	+$2.03M	0.01%	1512
2019 Q4	–	Sell	-77	Closed	-$19K	–	1775
2019 Q3	$19K	Buy	+77	New	+$25.1K	﹤0.01%	1600

Other funds holding DTIL

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Marshall Wace's DTIL Position: Q2 2026 in Review

Marshall Wace sold out of Precision BioSciences (DTIL) in Q2 2026, closing a stake of 415,671 shares — an estimated $2.29M sold.

Marshall Wace first reported a position in DTIL in Q3 2019 and held it in 11 quarters. The position peaked at $3.97M in Q2 2022. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

Marshall Wace reported no remaining Precision BioSciences position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 415,671 Precision BioSciences shares in Q2 2026, an estimated $2.29M.
Marshall Wace first reported a position in Precision BioSciences in Q3 2019 and held it in 11 quarters.
Marshall Wace's Precision BioSciences position peaked at $3.97M in Q2 2022.
95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.